Table 2 Patient-reported outcome scores at baseline (intention-to-treat population)
Patient-reported outcome | Sarilumab SC 200 mg q2w (n = 184) | Adalimumab SC 40 mg q2w (n = 185) |
|---|---|---|
HAQ-DIa | 1.6 (0.55) | 1.6 (0.64) |
Pain VASb | 71.6 (18.65) | 71.4 (18.96) |
PtGAb | 68.0 (17.49) | 67.8 (18.41) |
SF-36c | ||
 PCS | 30.7 (6.15) | 31.4 (6.59) |
 MCS | 36.7 (10.67) | 37.1 (11.83) |
 Physical functioning | 33.3 (20.04) | 35.7 (21.73) |
 Role physical | 34.4 (18.88) | 34.2 (20.08) |
 Bodily pain | 26.7 (14.75) | 28.4 (16.55) |
 General health | 34.4 (15.64) | 36.1 (16.21) |
 Vitality | 33.4 (16.42) | 35.5 (17.87) |
 Social functioning | 46.5 (23.23) | 47.4 (26.03) |
 Role emotional | 47.1 (24.44) | 47.4 (27.25) |
 Mental health | 49.0 (18.52) | 50.5 (19.69) |
FACIT-Fd | 23.6 (9.01) | 24.0 (10.31) |
Morning stiffness VASb | 70.8 (18.99) | 68.0 (21.37) |
RAID score (0–10)e | 6.7 (1.72) | 6.4 (2.03) |
WPS-RA | ||
 Employed outside the home, n (%) | 78 (42.6) | 69 (37.5) |
 Work days missed | 2.5 (5.26) | 2.0 (5.11) |
 Days with work productivity reduced by ≥ 50% | 5.8 (7.03) | 4.9 (7.66) |
 Interference with work productivityf | 5.6 (2.62) | 4.8 (2.98) |
 Housework days missed | 8.7 (8.14) | 7.3 (9.06) |
 Days with household productivity reduced by ≥ 50% | 10.0 (8.78) | 9.4 (9.68) |
 Interference with household productivity | 6.5 (2.60) | 6.3 (2.88) |
 Days with family, social, or leisure activities missed | 5.4 (7.84) | 5.6 (8.51) |
 Days with outside help hired | 5.2 (8.43) | 4.6 (8.57) |